Do analysts prefer KTTA or GNPX?

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 566.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, KTTA or GNPX?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Genprex N/A N/A -$16.23M -$310.77 N/A

Is KTTA or GNPX more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Genprex N/A -247.32% -176.73%

Does the media refer more to KTTA or GNPX?

In the previous week, Genprex had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 5 mentions for Genprex and 1 mentions for Pasithea Therapeutics. Genprex's average media sentiment score of 0.32 beat Pasithea Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genprex 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer BIVI or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BIVI or GNPX?

BioVie is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Genprex N/A N/A -$16.23M -$310.77 N/A

Is BIVI or GNPX more profitable?

BioVie's return on equity of -101.15% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Genprex N/A -247.32% -176.73%

Do analysts rate GNPX or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, GNPX or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Genprex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$310.77 N/A CytoMed Therapeutics $250K 39.75 -$3.10M N/A N/A

Is GNPX or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% CytoMed Therapeutics N/A N/A N/A

Do analysts rate CMMB or GNPX?

Chemomab Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 1,328.57%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, CMMB or GNPX?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Genprex N/A N/A -$16.23M -$310.77 N/A

Is CMMB or GNPX more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Genprex N/A -247.32% -176.73%

Do analysts prefer GNPX or SNTI?

Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 2,580.97%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is GNPX or SNTI more profitable?

Genprex's return on equity of -247.32% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Senti Biosciences N/A -532.05% -103.35%

Does the media prefer GNPX or SNTI?

In the previous week, Genprex had 4 more articles in the media than Senti Biosciences. MarketBeat recorded 5 mentions for Genprex and 1 mentions for Senti Biosciences. Genprex's average media sentiment score of 0.32 beat Senti Biosciences' score of 0.00 indicating that Genprex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Genprex (GNPX) Competitors

$4.44 +0.02 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$4.45 +0.01 (+0.29%)

As of 08:00 PM Eastern

Compare

GNPX vs. KTTA, BIVI, GDTC, CMMB, and SNTI

Should you buy Genprex stock or one of its competitors? MarketBeat compares Genprex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genprex include Pasithea Therapeutics (KTTA), BioVie (BIVI), CytoMed Therapeutics (GDTC), Chemomab Therapeutics (CMMB), and Senti Biosciences (SNTI). These companies are all part of the "biotechnology" industry.

How does Genprex compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A

Pasithea Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Genprex has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market.

In the previous week, Genprex had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 5 mentions for Genprex and 1 mentions for Pasithea Therapeutics. Genprex's average media sentiment score of 0.32 beat Pasithea Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genprex	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 566.67%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Pasithea Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pasithea Therapeutics' return on equity of -57.44% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Genprex	N/A	-247.32%	-176.73%

Summary

Pasithea Therapeutics beats Genprex on 10 of the 14 factors compared between the two stocks.

How does Genprex compare to BioVie?

BioVie (NASDAQ:BIVI) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

4.6% of BioVie shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 0.9% of BioVie shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Genprex had 5 more articles in the media than BioVie. MarketBeat recorded 5 mentions for Genprex and 0 mentions for BioVie. Genprex's average media sentiment score of 0.32 beat BioVie's score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Neutral
Genprex	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioVie has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Genprex has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

BioVie is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A

BioVie's return on equity of -101.15% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Genprex	N/A	-247.32%	-176.73%

Summary

BioVie and Genprex tied by winning 5 of the 10 factors compared between the two stocks.

How does Genprex compare to CytoMed Therapeutics?

Genprex (NASDAQ:GNPX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

CytoMed Therapeutics has higher revenue and earnings than Genprex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A
CytoMed Therapeutics	$250K	39.75	-$3.10M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
CytoMed Therapeutics	N/A	N/A	N/A

In the previous week, Genprex had 5 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 5 mentions for Genprex and 0 mentions for CytoMed Therapeutics. Genprex's average media sentiment score of 0.32 beat CytoMed Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Neutral
CytoMed Therapeutics	Neutral

Genprex has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

14.1% of Genprex shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CytoMed Therapeutics beats Genprex on 5 of the 9 factors compared between the two stocks.

How does Genprex compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Chemomab Therapeutics' return on equity of -89.03% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Genprex	N/A	-247.32%	-176.73%

Chemomab Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Genprex has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

In the previous week, Genprex had 5 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 5 mentions for Genprex and 0 mentions for Chemomab Therapeutics. Genprex's average media sentiment score of 0.32 beat Chemomab Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Genprex	Neutral

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A

Chemomab Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 1,328.57%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Chemomab Therapeutics beats Genprex on 10 of the 13 factors compared between the two stocks.

How does Genprex compare to Senti Biosciences?

Genprex (NASDAQ:GNPX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

14.1% of Genprex shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genprex has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$310.77	N/A
Senti Biosciences	$20K	580.95	-$61.44M	-$1.92	N/A

Genprex has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

Genprex's return on equity of -247.32% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Senti Biosciences	N/A	-532.05%	-103.35%

Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 2,580.97%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genprex had 4 more articles in the media than Senti Biosciences. MarketBeat recorded 5 mentions for Genprex and 1 mentions for Senti Biosciences. Genprex's average media sentiment score of 0.32 beat Senti Biosciences' score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Senti Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Senti Biosciences beats Genprex on 10 of the 15 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.23M	$3.58B	$6.87B	$12.98B
Dividend Yield	N/A	3.76%	2.60%	9.79%
P/E Ratio	-0.01	7.68	280.34	25.27
Price / Sales	N/A	1,307.74	600.21	92.32
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	0.08	17.16	12.97	6.09
Net Income	-$16.23M	-$12.52M	$3.49B	$347.95M
7 Day Performance	-37.64%	4.15%	3.57%	4.71%
1 Month Performance	-64.96%	-5.02%	-2.50%	-2.11%
1 Year Performance	-98.37%	50.34%	73.94%	20.58%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.7551 of 5 stars	$4.44 +0.5%	N/A	-98.4%	$2.23M	N/A	N/A	20	Gap Down
KTTA Pasithea Therapeutics	2.8901 of 5 stars	$0.46 +2.9%	$3.00 +556.5%	-35.2%	$11.40M	N/A	N/A	3	Positive News
BIVI BioVie	0.2501 of 5 stars	$1.52 +5.9%	N/A	-69.5%	$11.39M	N/A	N/A	10	Gap Up
GDTC CytoMed Therapeutics	0.9324 of 5 stars	$0.95 -4.5%	N/A	-54.2%	$11.18M	$250K	N/A	N/A	Gap Down
CMMB Chemomab Therapeutics	2.3872 of 5 stars	$1.51 -1.2%	$25.00 +1,554.5%	-58.0%	$10.88M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. KTTA, BIVI, GDTC, CMMB, and SNTI

How does Genprex compare to Pasithea Therapeutics?

Summary

How does Genprex compare to BioVie?

Summary

How does Genprex compare to CytoMed Therapeutics?

Summary

How does Genprex compare to Chemomab Therapeutics?

Summary

How does Genprex compare to Senti Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. KTTA, BIVI, GDTC, CMMB, and SNTI

How does Genprex compare to Pasithea Therapeutics?

Which has higher valuation & earnings, KTTA or GNPX?

Which has more risk and volatility, KTTA or GNPX?

Does the media refer more to KTTA or GNPX?

Do insiders and institutionals hold more shares of KTTA or GNPX?

Do analysts prefer KTTA or GNPX?

Is KTTA or GNPX more profitable?

Summary

How does Genprex compare to BioVie?

Do institutionals & insiders have more ownership in BIVI or GNPX?

Does the media favor BIVI or GNPX?

Do analysts prefer BIVI or GNPX?

Which has more volatility and risk, BIVI or GNPX?

Which has stronger earnings & valuation, BIVI or GNPX?

Is BIVI or GNPX more profitable?

Summary

How does Genprex compare to CytoMed Therapeutics?

Which has better earnings and valuation, GNPX or GDTC?

Do analysts rate GNPX or GDTC?

Is GNPX or GDTC more profitable?

Does the media prefer GNPX or GDTC?

Which has more risk and volatility, GNPX or GDTC?

Do institutionals & insiders believe in GNPX or GDTC?

Summary

How does Genprex compare to Chemomab Therapeutics?

Do institutionals and insiders have more ownership in CMMB or GNPX?

Is CMMB or GNPX more profitable?

Which has more risk & volatility, CMMB or GNPX?

Does the media refer more to CMMB or GNPX?

Which has better valuation & earnings, CMMB or GNPX?

Do analysts rate CMMB or GNPX?

Summary

How does Genprex compare to Senti Biosciences?

Do institutionals & insiders hold more shares of GNPX or SNTI?

Which has preferable earnings & valuation, GNPX or SNTI?

Which has more volatility and risk, GNPX or SNTI?

Is GNPX or SNTI more profitable?

Do analysts prefer GNPX or SNTI?

Does the media prefer GNPX or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools